Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 4029-4035

  Chauty, Annick ^a   Ardant, Marie Françoise ^a   Adeye, Ambroise ^a   Euverte, Hélène ^a   Guédénon, Augustin ^c   Johnson, Christian ^b   Aubry, Jacques ^d   Nuermberger, Eric ^e   Grosset, Jacques ^e  

^a Centre de Depistage et de Traitement de l'Ulcere de Buruli   (Benin)

^b Buruli Ulcer Control Programme   (Benin)

^c Fondation Raoul Follereau   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BURULI ULCER; CHILD; DRUG EFFICACY; EXCISION; FEMALE; FOLLOW UP; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIUM ULCERANS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN TRANSPLANTATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO; VESTIBULOCOCHLEAR NERVE DISEASE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BURULI ULCER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM ULCERANS; RIFAMPIN; STREPTOMYCIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 35848932800     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00175-07     Document Type: Article

References (25)

1. Amofah, G., S. Asamoah, and C. Afram-Gyening. 1998. Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana. Trop. Dr. 2:81-83.
2. Bentoucha, A., J. Robert, H. Dega, N. Lounis, V. Jarlier, and J. Grosset. 2001. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 45:3109-3112.
3. Debacker, M., J. Aguiar, C. Steunou, C. Zinsou, W. M. Meyers, and F. Portaels. 2005. Buruli ulcer recurrence, Benin. Emerg. Infect. Dis. 11:584-589.
4. Dega, H., J. Robert, P. Bonnafous, V. Jarlier, and J. Grosset. 2000. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 44:2367-2372.
5. Dega, H., A. Bentoucha, J. Robert, V. Jarlier, and J. Grosset. 2002. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 46:3193-3196.
6. Etuaful, S., B. Carbonnelle, J. Grosset, S. Lucas, C. Horsfield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, G. K. Amedofu, P. Awuah, E. Ampadu, G. Amofah, K. Asiedu, and M. Wansbrough-Jones. 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob. Agents Chemother. 49:3182-3186.
7. George, K. M., D. Chatterjee, G. Gunawardana, D. Welty, J. Hayman, R. Lee, and P. L. Small. 1999. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283:854-857.
8. George, K. M., L. Pascopella, D. M. Welty, and P. L. Small. 2000. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect. Immun. 68:877-883.
9. Ji, B., S. LeFrancois, J. Robert, A. Chaufour, C. Truffot, and V. Jarlier. 2006. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob. Agents Chemother. 50:1921-1926.
10. th WHO Advisory Group Meeting on Buruli Ulcer, 10-13 March 2003, WHO Headquarters, Geneva, Switzerland. World Health Organization, Geneva, Switzerland. (WHO/CDS/CDE/GBUI/2003.8).
11. Krieg, R. E., W. T. Hockmeyer, and D. H. Connor. 1974. Toxin of Mycobacterium ulcerans. Production and effects in guinea pig skin. Arch. Dermatol. 110:783-788.
12. Marsollier, L., G. Prevot, N. Honore, P. Legras, A. L. Manceau, C. Payan, H. Kouakou, and B. Carbonnelle. 2003. Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampin. Int. J. Antimicrob. Agents 22:562-566.
13. Marsollier, L., N. Honoré, P. Legras, A. L. Manceau, H. Kouakou, B. Carbonnelle, and S. T. Cole. 2003. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob. Agents Chemother. 47:1228-1232.
14. Muelder, K., and A. Nourou. 1990. Buruli ulcer in Benin. Lancet 336:1109-1111.
15. Portaels, F., H. Traore, K. De Ridder, and W. M. Meyers. 1998. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob. Agents Chemother. 42:2070-2073.
16. Portaels, F., J. Aguiar, M. Debacker, A. Guedenon, C. Steunou, C. Zinsou, and W. M. Meyers. 2004. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect. Immun. 72:62-65.
17. Revill, W. D. L., R. H. Morrow, M. C. Pike, and J. Ateng. 1973. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet ii:873-877.
18. Ross, B. C., L. Marino, F. Oppedisano, R. Edwards, R. M. Robins-Browne, and P. D. Johnson. 1997. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J. Clin. Microbiol. 35:1696-1700.
19. Sizaire, V., F. Nackers, E. Comte, and F. Portaels. 2006. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect. Dis. 6:288-296.
20. Stinear, T., B. C. Ross, J. K. Davies, L. Marino, R. M. Robins-Browne, F. Oppedisano, A. Sievers, and P. D. R. Johnson. 1999. Identification and characterization of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR. J. Clin. Microbiol. 37:1018-1023.
21. Stinear, T., J. K. Davies, G. A. Jenkin, F. Portaels, B. C. Ross, F. Oppedisano, M. Purcell, J. A. Hayman, and P. D. R. Johnson. 2000. A simple PCR method for rapid genotype analysis of Mycobacterium ulcerans. J. Clin. Microbiol. 38:1482-1487.
22. Thangaraj, H. S., O. Adjei, B. W. Allen, F. Portaels, M. R. W. Evans, D. K. Banerjee, and M. H. Wansbrough-Jones. 2000. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin, and rifampicin against Ghanaïan isolates of Mycobacterium ulcerans. J. Antimicrob. Chemother. 45:231-233.
23. Van der Werf, T. S., W. T. A. van der Graaf, J. W. Tappero, and K. Asiedu. 1999. Mycobacterium ulcerans infection. Lancet 354:1013-1018.
24. World Health Organization. 2002. The Buruli mysteries: unanswered questions surround a growing epidemic. WHO press release no. 16. World Health Organization, Geneva, Switzerland.
25. World Health Organization. 2004. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). World Health Organization, Geneva, Switzerland. WHO/CDS/CPE/GBUI/2004.10.